<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="935">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05148975</url>
  </required_header>
  <id_info>
    <org_study_id>145/21</org_study_id>
    <nct_id>NCT05148975</nct_id>
  </id_info>
  <brief_title>The Diagnosis of Superinfections in Mechanically Ventilated Covid-19 Patients</brief_title>
  <acronym>SUPER-BAL</acronym>
  <official_title>The Diagnosis of Superinfections in Mechanically Ventilated Covid-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brno University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Anne's University Hospital Brno, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brno University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with severe Coronavirus Disease 2019 (Covid-19) pneumonia depending on mechanical&#xD;
      ventilation are at risk of superinfections, especially infections of respiratory tract. This&#xD;
      multicententer prospective observational study is focused on early diagnosis of respiratory&#xD;
      tract superinfections and identification of risk factors (immunosuppressive therapy,...).&#xD;
      Investigators will use bronchoalveolar lavage fluid (BALF) for Polymerase Chain Reaction&#xD;
      (PCR) detection of pathogens and antigenic detection of mycoses.&#xD;
&#xD;
      This project can support the routine use of BALF and PCR diagnostics for early detection of&#xD;
      pathogens. Data will be compared with historical cohort of patients without routine BAL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, observational multicenter study&#xD;
&#xD;
      The inclusion criteria are as follows:&#xD;
&#xD;
      Age &gt; 18 years Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) PCR positivity in&#xD;
      the last 21 days Mechanical ventilation for Covid-19 pneumonia Presence of lung infiltrations&#xD;
      on the chest X-ray or ground glass opacity, crazy paving or lung infiltrations on the chest&#xD;
      CT Oxygenation disorder according to Acute Respiratory Distress Syndrome (ARDS) definition:&#xD;
      Partial Pressure of Oxygen in Arterial Blood (PaO2) / fraction of inspired oxygen (FiO2) &lt;300&#xD;
      mmHg with positive end expiratory pressure (PEEP) at least 5 cmH2O&#xD;
&#xD;
      The exclusion criteria are as follows:&#xD;
&#xD;
      Disagreement with the inclusion in the trial&#xD;
&#xD;
      Outcomes Primary outcome: incidence and characteristics of superinfections in patients with&#xD;
      Covid-19.&#xD;
&#xD;
      Secondary outcome:&#xD;
&#xD;
      Markers of infection/inflammation diagnostic values for the diagnosis of a specific type of&#xD;
      superinfection.&#xD;
&#xD;
      Comparison of the incidence of bacterial and opportunistic superinfections with a historical&#xD;
      cohort, where the extension of diagnostics with bronchoalveolar lavage was performed only in&#xD;
      patients who did not respond to antibacterial therapy&#xD;
&#xD;
      Size of the group of patients The number of patients enrolled in the study depends on the&#xD;
      epidemiological situation and the number of admitted patients with severe Covid-19 disease.&#xD;
      Investigators expect that the University Hospital at St. Anne's enrolls 75 patients and the&#xD;
      University Hospital Brno also enrolls 75 patients. The size of the group is not relevant due&#xD;
      to character of the study.&#xD;
&#xD;
      Monitored parameters Bronchoalveolar lavage (BAL) is the only procedure that differs from&#xD;
      standard care. It is usually performed in patients with a suspected lung infection that does&#xD;
      not respond to antibiotic therapy. In the study, BAL will be performed early after admission&#xD;
      and then in 7-day intervals ( ± 1 day). This interval can be shortened to a minimum of 3 days&#xD;
      if there are signs of a new lung infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 6, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Superinfection incidence</measure>
    <time_frame>1 year</time_frame>
    <description>The incidence and characteristics of superinfections in patients with Coronavirus Disease 2019 (COVID-19).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The aasociation inflammation diagnostic values and the diagnosis of superinfection</measure>
    <time_frame>1 year</time_frame>
    <description>Markers of infection / inflammation diagnostic values for the diagnosis of a specific type of superinfection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The differention of superinfection diagnosis between historical cohort and actual cohort.</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of the incidence of bacterial and opportunistic superinfections with a historical cohort, where the extension of diagnostics with bronchoalveolar lavage was performed only in patients who did not respond to antibacterial therapy.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <condition>Superinfection</condition>
  <condition>ARDS, Human</condition>
  <arm_group>
    <arm_group_label>Mild ARDS due to Covid- 19 pneumonia</arm_group_label>
    <description>Adults with SARS-CoV-2 PCR positivity in the last 21 days on mechanical ventilation for Covid-19 pneumonia, fulfilling criteria for mild acute respiratory distress syndrome (ARDS) definition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Bronchoalveolar lavage fluid diagnostics</intervention_name>
    <description>Bronchoalveolar lavage fluid diagnostics for superinfection in patients with COVID-19 pneumonia.</description>
    <arm_group_label>Mild ARDS due to Covid- 19 pneumonia</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Part of the sample from bronchoalveolar lavage fluid (BALF) will be frozen for possible&#xD;
      further analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with COVID-19 ARDS on mechanical ventilation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  SARS-CoV-2 PCR positivity in the last 21 days&#xD;
&#xD;
          -  Mechanical ventilation for Covid-19 pneumonia&#xD;
&#xD;
          -  Presence of lung infiltrations on the chest X-ray or ground glass opacity, crazy&#xD;
             paving or lung infiltrations on the chest CT&#xD;
&#xD;
          -  Oxygenation disorder according to ARDS definition: PaO2 / FiO2 &lt;300 mmHg with PEEP at&#xD;
             least 5 cmH2O&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disagreement with the inclusion in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jan Hudec, MD</last_name>
    <phone>+420532233850</phone>
    <email>hudec.jan@fnbrno.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan Maláska, MD, Ph.D.</last_name>
    <phone>+420532233850</phone>
    <email>hudec.jan@fnbrno.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <state>Czech Republic</state>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Annes University Hospital</name>
      <address>
        <city>Brno</city>
        <state>Czech Republic</state>
        <zip>65691</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Pavel Suk, MD, Ph.D.</last_name>
      <phone>+420543183537</phone>
      <email>pavel.suk@fnusa.cz</email>
    </contact>
    <investigator>
      <last_name>Pavel Suk, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>December 3, 2021</last_update_submitted>
  <last_update_submitted_qc>December 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brno University Hospital</investigator_affiliation>
    <investigator_full_name>Jan Hudec, MD</investigator_full_name>
    <investigator_title>physician</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>pneumonia</keyword>
  <keyword>superinfection</keyword>
  <keyword>bronchoalveolar lavage</keyword>
  <keyword>ARDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Superinfection</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 2, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT05148975/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

